Lumexa Imaging Holdings, Inc. Common Stock

Fundamentals0.0
Price Action6.0
News Sentiment0.0
AI Rating
6.0

Key Drivers

  • Rebound momentum
  • Near-term support
  • Resistance pressure

AI
AI Summary

6.0

LMRI is shifting from a simple turnaround story to a real test of whether higher advanced-modality mix and the HSS JV can convert into durable margin expansion, so the stock looks investable only if management can prove operating leverage beyond this quarter's early earnings inflection.

EarningsInflection
MarginRisk
Healthcare‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

0.0

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Rebound momentum
  • Near-term support
  • Resistance pressure

LMRI's short-term trend is bullish after rebounding from $10.26 to $12.03 over the last month, but it faces near-term resistance at $12.30–$12.35 and could weaken if $11.56 support breaks.

bullish
consolidation
Support Level: $11.56–$11.65
Resistance Level: $12.30–$12.35

Fast rebound from $10.26 to $12.03 over the last month shows strong but uneven momentum

Sentiment & News

0.0

Key News Insights:

  • Revenue growth
  • Volume rebound
  • Tighter outlook

Lumexa Imaging's Q2 showed stronger revenue, higher advanced-imaging volumes, and a return to profit, but management trimmed full-year EBITDA expectations, signaling better operations with a more cautious outlook. ക

Profitability
Guidance

The report is modestly supportive for Lumexa as improving execution offsets a more restrained profit forecast